 CAMBRIDGE, Mass. MONTREAL--BUSINESS WIRE--Repare Therapeutics Inc. Repare or the Company Nasdaq: RPTX, a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, will host a virtual Investor Day webcast today from 10:30 a.m. 12:00 p.m. ET, highlighting the progress of its proprietary RP-6306 program for tumors with genetic alterations characterized by CCNE1 amplification. The C 